Fesoterodine fumarate | CAS#286930-03-8 | 286930-02-7 | antimuscarinic

MedKoo Cat#: 317870 | Name: Fesoterodine Fumarate

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Fesoterodine is an antimuscarinic drug developed to treat overactive bladder syndrome (OAB). It was approved by the European Medicines Agency in April 2007, the US Food and Drug Administration on October 31, 2008 and Health Canada on February 9, 2012. Fesoterodine has the advantage of allowing more flexible dosage than other muscarinic antagonists. Its tolerability and side effects are similar to other muscarinic antagonists and as a new drug seems unlikely to make great changes in practices of treatment for overactive bladder.

Chemical Structure

Fesoterodine Fumarate

CAS#286930-03-8 (fumarate)

Theoretical Analysis

MedKoo Cat#: 317870

Name: Fesoterodine Fumarate

CAS#: 286930-03-8 (fumarate)

Chemical Formula: C30H41NO7

Exact Mass: 0.0000

Molecular Weight: 527.65

Elemental Analysis: C, 68.29; H, 7.83; N, 2.65; O, 21.22

Price and Availability

Size	Price	Availability	Quantity
25mg	USD 350.00	2 Weeks
100mg	USD 750.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

286930-03-8 (fumarate) 286930-02-7 (free base)

Synonym

Fesoterodine Fumarate; SPM-907; SPM 907; SPM907; SMP 8272; SMP8272; SMP-8272;

IUPAC/Chemical Name

(E)-but-2-enedioic acid;[2-[(1R)-3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl] 2-methylpropanoate

InChi Key

MWHXMIASLKXGBU-RNCYCKTQSA-N

InChi Code

InChI=1S/C26H37NO3.C4H4O4/c1-18(2)26(29)30-25-13-12-21(17-28)16-24(25)23(22-10-8-7-9-11-22)14-15-27(19(3)4)20(5)6;5-3(6)1-2-4(7)8/h7-13,16,18-20,23,28H,14-15,17H2,1-6H3;1-2H,(H,5,6)(H,7,8)/b;2-1+/t23-;/m1./s1

SMILES Code

O=C(O)/C=C/C(O)=O.CC(C)C(OC1=CC=C(CO)C=C1[C@@H](C2=CC=CC=C2)CCN(C(C)C)C(C)C)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Certificate of Analysis

View CoA: current batch, Lot#A20K08S06

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 527.65 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Gomelsky A, Dmochowski RR. Fesoterodine fumarate. Drugs Today (Barc). 2010 Feb;46(2):81-90. doi: 10.1358/dot.2010.46.2.1437712. PMID: 20393636. 2: Rantell A, Cardozo L, Srikrishna S. Fesoterodine fumarate and the oxybutynin ring for the treatment of urinary incontinence in women. Expert Opin Pharmacother. 2014 Feb;15(3):385-93. doi: 10.1517/14656566.2014.875158. Epub 2013 Dec 27. PMID: 24369895. 3: Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. Fesoterodine. 2021 Aug 16. PMID: 29999896. 4: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. Fesoterodine. 2023 Jul 12. PMID: 31644117. 5: Mock S, Dmochowski RR. Evaluation of fesoterodine fumarate for the treatment of an overactive bladder. Expert Opin Drug Metab Toxicol. 2013 Dec;9(12):1659-66. doi: 10.1517/17425255.2013.858118. Epub 2013 Nov 9. PMID: 24205892. 6: McKeage K, Keating GM. Fesoterodine. Drugs. 2009;69(6):731-8. doi: 10.2165/00003495-200969060-00006. PMID: 19405552. 7: Gamé X, Peyronnet B, Cornu JN. Fesoterodine: Pharmacological properties and clinical implications. Eur J Pharmacol. 2018 Aug 15;833:155-157. doi: 10.1016/j.ejphar.2018.05.036. Epub 2018 May 24. PMID: 29803689. 8: Yonguc T, Sefik E, Inci I, Kusbeci OY, Celik S, Aydın ME, Polat S. Randomized, controlled trial of fesoterodine fumarate for overactive bladder in Parkinson's disease. World J Urol. 2020 Aug;38(8):2013-2019. doi: 10.1007/s00345-019-02981-7. Epub 2019 Oct 23. PMID: 31642953. 9: Konstantinidis C, Samarinas M, Tzitzika M, Kratiras Z, Panagiotakopoulos G, Giannitsas K, Athanasopoulos A. Efficacy of fesoterodine fumarate (8 mg) in neurogenic detrusor overactivity due to spinal cord lesion or multiple sclerosis: A prospective study. Neurourol Urodyn. 2021 Nov;40(8):2026-2033. doi: 10.1002/nau.24790. Epub 2021 Sep 9. PMID: 34498773. 10: Vella M, Cardozo L. Review of fesoterodine. Expert Opin Drug Saf. 2011 Sep;10(5):805-8. doi: 10.1517/14740338.2011.591377. Epub 2011 Jun 4. PMID: 21639817. 11: Chapple C, Oelke M, Kaplan SA, Scholfield D, Arumi D, Wagg AS. Fesoterodine clinical efficacy and safety for the treatment of overactive bladder in relation to patient profiles: a systematic review. Curr Med Res Opin. 2015 Jun;31(6):1201-43. doi: 10.1185/03007995.2015.1032917. Epub 2015 Apr 23. PMID: 25798911. 12: Heesakkers J, Te Dorsthorst M, Wagg A. Safety and Tolerability of Fesoterodine in Older Adult Patients with Overactive Bladder. Can Geriatr J. 2022 Mar 2;25(1):72-78. doi: 10.5770/cgj.25.530. PMID: 35310472; PMCID: PMC8887709. 13: Wyndaele JJ, Schneider T, MacDiarmid S, Scholfield D, Arumi D. Flexible dosing with fesoterodine 4 and 8 mg: a systematic review of data from clinical trials. Int J Clin Pract. 2014 Jul;68(7):830-40. doi: 10.1111/ijcp.12425. Epub 2014 Apr 22. PMID: 24754814. 14: Cosse C, Chaigne B, Plaisant S, Chouchana L, Mouthon L. Digital Ischemia Induced by Fesoterodine. J Clin Rheumatol. 2021 Sep 1;27(6):e212-e213. doi: 10.1097/RHU.0000000000000932. PMID: 30431489. 15: Gupta K, Kaur K, Aulakh BS, Kaushal S. Fesoterodine for overactive bladder: A review of the literature. Curr Ther Res Clin Exp. 2010 Oct;71(5):273-88. doi: 10.1016/j.curtheres.2010.10.003. PMID: 24688149; PMCID: PMC3969610. 16: Tzefos M, Dolder C, Olin JL. Fesoterodine for the treatment of overactive bladder. Ann Pharmacother. 2009 Dec;43(12):1992-2000. doi: 10.1345/aph.1M308. Epub 2009 Nov 17. PMID: 19920160. 17: Angulo JC, Valpas A, Rejas J, Linden K, Kvasz M, Snedecor SJ. Cost effectiveness of fesoterodine and tolterodine for the treatment of overactive bladder with urge urinary incontinence in Spain and Finland. Clin Drug Investig. 2014 May;34(5):297-307. doi: 10.1007/s40261-014-0178-1. PMID: 24567280. 18: Dell'Utri C, Digesu GA, Bhide A, Khullar V. Fesoterodine in randomised clinical trials: an updated systematic clinical review of efficacy and safety. Int Urogynecol J. 2012 Oct;23(10):1337-44. doi: 10.1007/s00192-012-1696-0. Epub 2012 Mar 13. PMID: 22411206. 19: Mansfield KJ. Role of fesoterodine in the treatment of overactive bladder. Open Access J Urol. 2009 Dec 17;2:1-9. doi: 10.2147/rru.s5171. PMID: 24198608; PMCID: PMC3818872. 20: Biardeau X, Przydacz M, Aharony S, Loutochin G, Campeau L, Kyheng M, Corcos J. Early Fesoterodine Fumarate Administration Prevents Neurogenic Detrusor Overactivity in a Spinal Cord Transected Rat Model. PLoS One. 2017 Jan 6;12(1):e0169694. doi: 10.1371/journal.pone.0169694. PMID: 28060912; PMCID: PMC5217950.